LATEST NEWS: UCB faces U.S. patent challenge for epilepsy drug - BRUSSELS (Reuters) - The U.S. Patent and Trademark Office (PTO) is to review UCB's patent for its epilepsy drug Vimpat, the latest round in a legal battle between the Belgian pharmaceutical company and generic rivals.
LATEST NEWS: GSK lung drug succeeds in big UK study, after earlier miss - LONDON (Reuters) - GlaxoSmithKline's new inhaled medicine Breo proved significantly better than standard care in a large British study that tested it in everyday use, providing a fillip for the product after the failure of another big trial in 2015.
LATEST NEWS: States on Zika's frontline see big gaps in funding, expertise - (Reuters) - In Mississippi, a small team of entomologists has begun the first survey of mosquito populations in decades. Experts do not believe the kind of mosquitoes most likely to carry the Zika virus are active in the state, but they cannot know for sure.
LATEST NEWS: FDA staff question usefulness of Sanofi diabetes drugs - (Reuters) - A preliminary review by the U.S. Food and Drug Administration questioned the usefulness of a combination diabetes drug made by Sanofi SA's and said it was unclear whether one component, lixisenatide, contributed to its benefit.
LATEST NEWS: France faults Bial and Biotrial over fatal drug trial - PARIS (Reuters) - Portuguese drugmaker Bial and French laboratory Biotrial are at fault "on several counts" for a failed drug trial that left one person dead and five others hospitalized in January, French Health Minister Marisol Touraine said on Monday.